News | Hemostasis Management | October 27, 2021

Teleflex Completes Enrollment in IDE Study of QuickClot in Cardiac Surgery

Study Evaluates Effectiveness of QuikClot Control+ Hemostatic Device in Patients Undergoing Cardiac Surgeryteleflex.com

QuickClot already has an FDA-cleared product for use for vascular access hemostasis management in cath lab procedures. The hemostatic technology consists of a non-woven material impregnated with kaolin, an inorganic mineral. When kaolin contacts blood it activates Factor XII, which accelerates the body’s natural clotting cascade.

QuickClot uses a non-woven material impregnated with kaolin, an inorganic mineral. When kaolin contacts blood it activates Factor XII, which accelerates the body’s natural clotting cascade.


October 27, 2021 — Teleflex Inc. announced the completion of patient enrollment in a clinical study evaluating the performance of the QuikClot Control+ hemostatic device for mild to moderate (Class I and II) bleeding in cardiac procedures as compared to standard gauze.

QuickClot already has an FDA-cleared product for use for vascular access hemostasis management in cath lab procedures. The hemostatic technology consists of a non-woven material impregnated with kaolin, an inorganic mineral. When kaolin contacts blood it activates Factor XII, which accelerates the body’s natural clotting cascade.

The primary efficacy endpoint of this prospective, randomized, controlled Cardiac Investigational Device Exemption (IDE) Study is the rate at which subjects achieved hemostasis through 10 minutes of hemostatic application and compression at the bleeding site. The secondary efficacy endpoint is the proportion of subjects achieving hemostasis measured at 5 and 10 minutes. The study enrolled 231 patients across seven investigational sites in the U.S. and completed enrollment three months ahead of schedule.


The principal investigators of the Cardiac IDE study include Mubashir A. Mumtaz, M.D., chief of cardiothoracic surgery and surgical director of the structural heart program at UPMC Central Pennsylvania, and Marc Moon, M.D., section chief of cardiac surgery, at Washington University School of Medicine in St. Louis and past-president of the American Association for Thoracic Surgery (STS).

“We are pleased to participate in this study to explore the use of the QuikClot Control+ Hemostatic Device in cardiac surgery,” Mumtaz said. “We look forward to sharing the results of its use in various aspects of cardiac surgery including coronary artery bypass grafting (CABG), valve repair/replacement, and thoracic aortic surgeries.”

The QuikClot Control+ Hemostatic Device is the first FDA-cleared hemostatic dressing indicated for severe (Class III and IV) bleeding in the internal organ space and is currently commercially available in the U.S. The product is considered an investigational device for clinical evaluation in the Cardiac IDE study.

“More than 600,000 cardiothoracic procedures are performed in the U.S. each year, according to Teleflex research,” said Kevin Robinson, president and general manager, anesthesia and emergency medicine division, Teleflex. “Our goal is to offer surgeons another tool to support positive patient outcomes in these procedures. We anticipate submitting a 510(k) filing for expanded use of the QuikClot Control+ Device following completion of the study analysis.”

For more information: teleflex.com


Related Content

News | Cardiovascular Surgery

November 2, 2023 — The University of Maryland Medical Center (UMMC) released a statement on the passing of a patient ...

Home November 02, 2023
Home
News | Cardiovascular Surgery

October 25, 2023 — Edwards Lifesciences announced new data from the PARTNER 3 trial demonstrating continued low rates of ...

Home October 25, 2023
Home
News | Cardiovascular Surgery

October 18, 2023 — A study published in The Annals of Thoracic Surgery demonstrates outstanding long-term survival ...

Home October 18, 2023
Home
News | Cardiovascular Surgery

October 18, 2023 — Walgreens and the Cardiovascular Research Foundation (CRF) announced a collaboration to drive forward ...

Home October 18, 2023
Home
News | Cardiovascular Surgery

April 21, 2023 — A Michigan Medicine study finds that Black and socioeconomically disadvantaged patients with a common ...

Home April 21, 2023
Home
News | Cardiovascular Surgery

March 24, 2023 — The American College of Surgeons (ACS), with the Society for Vascular Surgery (SVS), has launched a new ...

Home March 24, 2023
Home
News | Cardiovascular Surgery

March 15, 2023 — Researchers at the University of Alabama at Birmingham Marnix E. Heersink School of Medicine published ...

Home March 15, 2023
Home
News | Cardiovascular Surgery

February 7, 2023 — A scientific session devoted to identifying and closing gaps in health care took place January 21 ...

Home February 07, 2023
Home
News | Cardiovascular Surgery

January 31, 2023 — Serotonin can impact the mitral valve of the heart and potentially accelerate a cardiac condition ...

Home January 31, 2023
Home
News | Cardiovascular Surgery

December 30, 2022 — Azmi Atiya, MD, an established and highly respected cardiothoracic surgeon in the San Fernando ...

Home December 30, 2022
Home
Subscribe Now